Business
Reliance Global Group Signs Term Sheet to Acquire Majority Stake in Israeli AI Diagnostic Company, Scentech, Positioning for Entry into the Multi-Billion Dollar Early Disease Detection Market
Transaction structured to achieve majority ownership through performance-based clinical and regulatory milestones Marks first strategic acquisition for new
About this update from Reliance Global Group, Inc.
[{"type":"text","content":"Transaction structured to achieve majority ownership through performance-based clinical and regulatory milestones Marks first strategic acquisition for new division—Ezra International Group Lakewood, NJ, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (NASDAQ: RELI) (“Reliance” or the “Company”) today announced that it has entered into a non-binding term sheet (“the term sheet”) to acquire a majority equity position of Scent Medical Technologies Ltd (“Scentech”). Scentech is a diagnostics company developing artificial intelligence technologies designed to identify disease-associated molecular signatures in human breath. Scentech’s product candidates are under development and have not yet been clinically validated or approved for commercial use. Any potential clinical or commercial outcomes remain subject to successful clinical validation and applicable regulatory clearances or approvals. The proposed transaction is expected to become the first asset within Ezra International Group, Reliance’s newly established division focused on strategic investments in technology-driven companies. Scentech’s AI technology platforms include VOX™, a non-invasive breath-based diagnostic product candidate under development for early pancreatic cancer risk assessment, and VocTracer™, a laboratory-based system product candidate designed to detect biochemical signatures associated with healthcare-associated infections (“HAIs”) and antimicrobial resistance (“AMR”) potentially earlier than conventional culture readouts, subject to validation. Scentech is developing a multi-indication detection platform product candidate based on the ability to identify disease-related biomarkers through molecular signatures in human breath. Subject to ongoing development and validation, these signatures are expected to be identified through non-invasive sampling or routine laboratory workflows using the Scentech artificial intelligence combined with specialized instrumentation. Scentech’s initial development intends to address two areas of high unmet need: Pancreatic cancer is one of the deadliest major solid tumors. Scentech’s technology is designed to enable earlier detection.Healthcare-associated infections and antimicrobial resistance, which contribute to extended hospital stays, increased mortality, and excess healthcare costs. Scentech’s platform is...